Letters Drug safety reporting A major rethink is needed on reporting adverse drug reactions BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e6379 (Published 24 September 2012) Cite this as: BMJ 2012;345:e6379 Article Related content Metrics Responses Peer review Related articles Editorial Drug safety: reporting systems for the general public Published: 07 August 2012; BMJ 345 doi:10.1136/bmj.e4916 See more Doctors, their leaders, and the drug policy debate BMJ November 14, 2016, 355 i6087; DOI: https://doi.org/10.1136/bmj.i6087 Revisiting the drug interaction between tamoxifen and SSRI antidepressants BMJ September 30, 2016, 354 i5309; DOI: https://doi.org/10.1136/bmj.i5309 Cold feet BMJ September 05, 2016, 354 i4584; DOI: https://doi.org/10.1136/bmj.i4584 US drug labels to warn of risks of combining opioids and benzodiazepines BMJ September 02, 2016, 354 i4784; DOI: https://doi.org/10.1136/bmj.i4784 US states that allow medical marijuana see drop in prescriptions for other drugs, study finds BMJ July 14, 2016, 354 i3942; DOI: https://doi.org/10.1136/bmj.i3942
